{"id":12444,"date":"2025-07-30T17:26:30","date_gmt":"2025-07-30T15:26:30","guid":{"rendered":"https:\/\/www.kliinikum.ee\/yhendlabor\/?page_id=12444"},"modified":"2025-12-11T17:10:00","modified_gmt":"2025-12-11T15:10:00","slug":"adalimumab-ja-adalimumabi-vastaste-antikehade-hulk-seerumis-s-adalimumab-s-adalimumab-ab-qn","status":"publish","type":"page","link":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/adalimumab-ja-adalimumabi-vastaste-antikehade-hulk-seerumis-s-adalimumab-s-adalimumab-ab-qn\/","title":{"rendered":"Adalimumab ja adalimumabi-vastaste antikehade hulk seerumis (S-Adalimumab, S-Adalimumab Ab QN)"},"content":{"rendered":"\n

Kliinilise keemia ja laboratoorse hematoloogia osakond<\/em><\/p>\n\n\n\n

Adalimumab <\/strong>on bioloogilise ravimina kasutatav rekombinantne inimese monoklonaalne antikeha. See seostub spetsiifiliselt TNF\u03b1-ga, neutraliseerides TNF\u03b1 toime\u00a0 ja p\u00e4rssides seekaudu p\u00f5letikulist reaktsiooni. Adalimumabi kasutatakse nt reumatoidartriidi, psoriaatilise artriidi, ank\u00fcloseeriva spond\u00fcliidi, p\u00f5letikuliste soolehaiguste jt ravis. Adalimumabi baaskontsentratsioon seerumis korreleerub h\u00e4sti ravi efektiivsusega.<\/p>\n\n\n\n

Ravi k\u00e4igus v\u00f5ivad m\u00f5nel patsiendil tekkida adalimumabi-vastased antikehad, mist\u00f5ttu ravimi kontsentratsioon seerumis ja raviefekt v\u00e4henevad. Samuti v\u00f5ivad antikehad p\u00f5hjustada lokaalseid k\u00f5rvaltoimeid.<\/p>\n\n\n\n

Lisaks s\u00f5ltub ravimi kontsentratsioon seerumis veel ravimi doosist ja manustamise sagedusest, haiguse fenot\u00fc\u00fcbist ja aktiivsusastmest, teistest samaaegselt manustatavatest ravimitest ja farmakogeneetilistest faktoritest.<\/p>\n\n\n\n

Uuritav materjal, selle v\u00f5tmine, saatmine ja s\u00e4ilitamine<\/strong><\/p>\n\n\n\n

Oluline on v\u00f5tta veri uuringuks vahetult enne j\u00e4rgmist ravimi annust (baaskontsentratsioon)!<\/p>\n\n\n\n

<\/td>Katsuti<\/strong><\/td>Geeli ja h\u00fc\u00fcbimisaktivaatoriga katsuti (punane kollase r\u00f5ngaga kork v\u00f5i kollane kork)<\/td><\/tr>
<\/td>S\u00e4ilivus<\/strong><\/td>Seerum toatemperatuuril kolm p\u00e4eva, +4 \u00b0C kaheksa p\u00e4eva<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Anal\u00fc\u00fcsi tegemise aeg:<\/strong> kord n\u00e4dalas<\/p>\n\n\n\n

Anal\u00fc\u00fcsimeetod: <\/strong>kemoluminestsents-immuunmeetod (CLIA)<\/p>\n\n\n\n

Referentsv\u00e4\u00e4rtused<\/strong><\/p>\n\n\n\n

Adalimumabi terapeutiline kontsentratsioon s\u00f5ltub patsiendi diagnoosist ja v\u00f5ib erinevate kirjandusallikate p\u00f5hjal olla vahemikus 4,5 mg\/L kuni 12 mg\/L.<\/p>\n\n\n\n

Adalimumabi vastased antikehad <\/strong><\/p>\n\n\n\n

<\/td>< 10 \u00b5g\/L<\/strong><\/td>negatiivne<\/td><\/tr>
<\/td>\u2265 10 \u00b5g\/L<\/strong><\/td>positiivne<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

N\u00e4idustus ja kliiniline t\u00e4hendus<\/strong><\/p>\n\n\n\n

Adalimumab-ravi j\u00e4lgimine (nii proaktiivne j\u00e4lgimine kui v\u00e4henenud raviefekti p\u00f5hjuste selgitamine).<\/p>\n\n\n\n

Kui adalimumabi kontsentratsioon on subterapeutiline, kuid antikehasid ei esine, v\u00f5ib parema raviefekti saavutamiseks olla abi ravimi doosi t\u00f5stmisest v\u00f5i manustamisintervalli l\u00fchendamisest. Juhul, kui antikehad on positiivsed, siis ravimannuse suurendamine efekti ei anna ja tuleb m\u00f5elda alternatiivsetele ravivalikutele.<\/p>\n\n\n\n

Terapeutilisest vahemikust k\u00f5rgem kontsentratsioon ei suurenda raviefekti ega anna t\u00e4iendavat kasu.<\/p>\n\n\n\n

Koostaja: Kaja Vaagen
Koostatud 06.08.2024<\/p>\n","protected":false},"excerpt":{"rendered":"

Kliinilise keemia ja laboratoorse hematoloogia osakond Adalimumab on bioloogilise ravimina kasutatav rekombinantne inimese monoklonaalne antikeha. See seostub spetsiifiliselt TNF\u03b1-ga, neutraliseerides TNF\u03b1 toime\u00a0 ja p\u00e4rssides seekaudu p\u00f5letikulist reaktsiooni. Adalimumabi kasutatakse nt reumatoidartriidi, psoriaatilise artriidi, ank\u00fcloseeriva spond\u00fcliidi, p\u00f5letikuliste soolehaiguste jt ravis. Adalimumabi baaskontsentratsioon seerumis korreleerub h\u00e4sti ravi efektiivsusega. Ravi k\u00e4igus v\u00f5ivad m\u00f5nel patsiendil tekkida adalimumabi-vastased antikehad, mist\u00f5ttu […]<\/p>\n","protected":false},"author":38,"featured_media":0,"parent":7301,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_uag_custom_page_level_css":"","footnotes":""},"class_list":["post-12444","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nAdalimumab ja adalimumabi-vastaste antikehade hulk seerumis (S-Adalimumab, S-Adalimumab Ab QN) - \u00dchendlabor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/adalimumab-ja-adalimumabi-vastaste-antikehade-hulk-seerumis-s-adalimumab-s-adalimumab-ab-qn\/\" \/>\n<meta property=\"og:locale\" content=\"et_EE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adalimumab ja adalimumabi-vastaste antikehade hulk seerumis (S-Adalimumab, S-Adalimumab Ab QN) - \u00dchendlabor\" \/>\n<meta property=\"og:description\" content=\"Kliinilise keemia ja laboratoorse hematoloogia osakond Adalimumab on bioloogilise ravimina kasutatav rekombinantne inimese monoklonaalne antikeha. See seostub spetsiifiliselt TNF\u03b1-ga, neutraliseerides TNF\u03b1 toime\u00a0 ja p\u00e4rssides seekaudu p\u00f5letikulist reaktsiooni. Adalimumabi kasutatakse nt reumatoidartriidi, psoriaatilise artriidi, ank\u00fcloseeriva spond\u00fcliidi, p\u00f5letikuliste soolehaiguste jt ravis. Adalimumabi baaskontsentratsioon seerumis korreleerub h\u00e4sti ravi efektiivsusega. Ravi k\u00e4igus v\u00f5ivad m\u00f5nel patsiendil tekkida adalimumabi-vastased antikehad, mist\u00f5ttu […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/adalimumab-ja-adalimumabi-vastaste-antikehade-hulk-seerumis-s-adalimumab-s-adalimumab-ab-qn\/\" \/>\n<meta property=\"og:site_name\" content=\"\u00dchendlabor\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-11T15:10:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutit\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/adalimumab-ja-adalimumabi-vastaste-antikehade-hulk-seerumis-s-adalimumab-s-adalimumab-ab-qn\\\/\",\"url\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/adalimumab-ja-adalimumabi-vastaste-antikehade-hulk-seerumis-s-adalimumab-s-adalimumab-ab-qn\\\/\",\"name\":\"Adalimumab ja adalimumabi-vastaste antikehade hulk seerumis (S-Adalimumab, S-Adalimumab Ab QN) - \u00dchendlabor\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/#website\"},\"datePublished\":\"2025-07-30T15:26:30+00:00\",\"dateModified\":\"2025-12-11T15:10:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/adalimumab-ja-adalimumabi-vastaste-antikehade-hulk-seerumis-s-adalimumab-s-adalimumab-ab-qn\\\/#breadcrumb\"},\"inLanguage\":\"et\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/adalimumab-ja-adalimumabi-vastaste-antikehade-hulk-seerumis-s-adalimumab-s-adalimumab-ab-qn\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/adalimumab-ja-adalimumabi-vastaste-antikehade-hulk-seerumis-s-adalimumab-s-adalimumab-ab-qn\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"K\u00e4siraamat\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Ravimiseire uuringud\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Adalimumab ja adalimumabi-vastaste antikehade hulk seerumis (S-Adalimumab, S-Adalimumab Ab QN)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/#website\",\"url\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/\",\"name\":\"\u00dchendlabor\",\"description\":\"Hoolivus, Uuendusmeelsus, P\u00e4devus ja Usaldusv\u00e4\u00e4rsus\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"et\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adalimumab ja adalimumabi-vastaste antikehade hulk seerumis (S-Adalimumab, S-Adalimumab Ab QN) - \u00dchendlabor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/adalimumab-ja-adalimumabi-vastaste-antikehade-hulk-seerumis-s-adalimumab-s-adalimumab-ab-qn\/","og_locale":"et_EE","og_type":"article","og_title":"Adalimumab ja adalimumabi-vastaste antikehade hulk seerumis (S-Adalimumab, S-Adalimumab Ab QN) - \u00dchendlabor","og_description":"Kliinilise keemia ja laboratoorse hematoloogia osakond Adalimumab on bioloogilise ravimina kasutatav rekombinantne inimese monoklonaalne antikeha. See seostub spetsiifiliselt TNF\u03b1-ga, neutraliseerides TNF\u03b1 toime\u00a0 ja p\u00e4rssides seekaudu p\u00f5letikulist reaktsiooni. Adalimumabi kasutatakse nt reumatoidartriidi, psoriaatilise artriidi, ank\u00fcloseeriva spond\u00fcliidi, p\u00f5letikuliste soolehaiguste jt ravis. Adalimumabi baaskontsentratsioon seerumis korreleerub h\u00e4sti ravi efektiivsusega. Ravi k\u00e4igus v\u00f5ivad m\u00f5nel patsiendil tekkida adalimumabi-vastased antikehad, mist\u00f5ttu […]","og_url":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/adalimumab-ja-adalimumabi-vastaste-antikehade-hulk-seerumis-s-adalimumab-s-adalimumab-ab-qn\/","og_site_name":"\u00dchendlabor","article_modified_time":"2025-12-11T15:10:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutit"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/adalimumab-ja-adalimumabi-vastaste-antikehade-hulk-seerumis-s-adalimumab-s-adalimumab-ab-qn\/","url":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/adalimumab-ja-adalimumabi-vastaste-antikehade-hulk-seerumis-s-adalimumab-s-adalimumab-ab-qn\/","name":"Adalimumab ja adalimumabi-vastaste antikehade hulk seerumis (S-Adalimumab, S-Adalimumab Ab QN) - \u00dchendlabor","isPartOf":{"@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/#website"},"datePublished":"2025-07-30T15:26:30+00:00","dateModified":"2025-12-11T15:10:00+00:00","breadcrumb":{"@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/adalimumab-ja-adalimumabi-vastaste-antikehade-hulk-seerumis-s-adalimumab-s-adalimumab-ab-qn\/#breadcrumb"},"inLanguage":"et","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/adalimumab-ja-adalimumabi-vastaste-antikehade-hulk-seerumis-s-adalimumab-s-adalimumab-ab-qn\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/adalimumab-ja-adalimumabi-vastaste-antikehade-hulk-seerumis-s-adalimumab-s-adalimumab-ab-qn\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/"},{"@type":"ListItem","position":2,"name":"K\u00e4siraamat","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/"},{"@type":"ListItem","position":3,"name":"Ravimiseire uuringud","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/"},{"@type":"ListItem","position":4,"name":"Adalimumab ja adalimumabi-vastaste antikehade hulk seerumis (S-Adalimumab, S-Adalimumab Ab QN)"}]},{"@type":"WebSite","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/#website","url":"https:\/\/www.kliinikum.ee\/yhendlabor\/","name":"\u00dchendlabor","description":"Hoolivus, Uuendusmeelsus, P\u00e4devus ja Usaldusv\u00e4\u00e4rsus","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.kliinikum.ee\/yhendlabor\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"et"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false},"uagb_author_info":{"display_name":"Kadi Siigur","author_link":"https:\/\/www.kliinikum.ee\/yhendlabor\/author\/kadisi\/"},"uagb_comment_info":0,"uagb_excerpt":"Kliinilise keemia ja laboratoorse hematoloogia osakond Adalimumab on bioloogilise ravimina kasutatav rekombinantne inimese monoklonaalne antikeha. See seostub spetsiifiliselt TNF\u03b1-ga, neutraliseerides TNF\u03b1 toime\u00a0 ja p\u00e4rssides seekaudu p\u00f5letikulist reaktsiooni. Adalimumabi kasutatakse nt reumatoidartriidi, psoriaatilise artriidi, ank\u00fcloseeriva spond\u00fcliidi, p\u00f5letikuliste soolehaiguste jt ravis. Adalimumabi baaskontsentratsioon seerumis korreleerub h\u00e4sti ravi efektiivsusega. Ravi k\u00e4igus v\u00f5ivad m\u00f5nel patsiendil tekkida adalimumabi-vastased antikehad, mist\u00f5ttu…","_links":{"self":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/12444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/comments?post=12444"}],"version-history":[{"count":0,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/12444\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/7301"}],"wp:attachment":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/media?parent=12444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}